SCHEMBL14712967

SCHEMBL14712967

CCN1C(=O)C(=C/C=C/c2ccccc2)C(=O)N(CC)C1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 14/20 0.53
APP P05067 4/20 0.53
SNCA P37840 4/20 0.53
KMT2A Q03164 9/20 0.52
ALDH1A1 P00352 9/20 0.52
MAPK1 P28482 8/20 0.52
MEN1 O00255 7/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
PKM P14618 3/20 0.52
MITF O75030 2/20 0.52
CMA1 P23946 1/20 0.51
POLB P06746 5/20 0.49
L3MBTL1 Q9Y468 4/20 0.49
LMNA P02545 4/20 0.49
TDP1 Q9NUW8 3/20 0.49
KDM4E B2RXH2 3/20 0.49
HTT P42858 2/20 0.49
MDM2 Q00987 2/20 0.49
THRB P10828 1/20 0.49
HPGD P15428 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14712965 0.88 MAPT (0.64) MAPTAPPSNCAKMT2AALDH1A1
SCHEMBL14712892 0.82 MAPT (0.72) MAPTAPPSNCAKMT2AALDH1A1
SCHEMBL14712995 0.82 BCL2A1 (0.61) MAPTAPPSNCAKMT2AALDH1A1
SCHEMBL14712869 0.82 BCL2A1 (0.61) MAPTAPPSNCAKMT2AALDH1A1
SCHEMBL16713171 0.82 MAPT (0.71) MAPTAPPSNCAKMT2AALDH1A1
SCHEMBL16713172 0.82 MAPT (0.71) MAPTAPPSNCAKMT2AALDH1A1
SCHEMBL14713054 0.81 MAPT (0.42) MAPTAPPSNCAKMT2AALDH1A1
SCHEMBL14712964 0.80 MAPT (0.61) MAPTAPPSNCAKMT2AALDH1A1
SCHEMBL20156788 0.80 MAPT (0.42) MAPTAPPSNCAKMT2AALDH1A1
SCHEMBL14713047 0.79 APP (0.60) MAPTAPPSNCAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
WO-2013024447-A1 COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAX MAPT 2828/4885APP 4756/4885SNCA 4356/4885
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAK1 MAPT 3272/4885APP 4689/4885SNCA 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.